We are committed to improving the lives of companion animals by developing innovative biotherapeutics to address cancer and osteoarthritis.
Our Mission
At VetrixBio, we believe pets deserve better medicine. Millions of dogs and cats live with chronic conditions that are often underdiagnosed, undertreated, or managed with limited options.
Our mission is to change that by developing therapies that not only relieve symptoms, but meaningfully improve quality of life and long-term outcomes.
We are focused on advancing a new generation of treatments that bring the rigor of human biotechnology into veterinary care, helping veterinarians do more for the animals and families they serve.
Translating Human Therapeutics into Veterinary Breakthroughs
As part of a broader strategy to bring proven human drug modalities into animal health, we utilize advanced discovery and engineering platforms to identify and optimize therapies for cancer and osteoarthritis in pets.
In collaboration with our partners, we apply next-generation screening approaches built on expansive libraries of canine-derived antibodies and protein scaffolds, comprising billions of distinct candidates. These libraries are systematically evaluated against well-characterized targets, many of which have been clinically validated in human medicine, to isolate molecules with strong binding affinity and the functional properties required for therapeutic activity. Leading candidates are then advanced into further validation and preclinical development.
For peptide and protein-based therapies, we combine computational biology with precision protein engineering to convert recombinant molecules into material-binding variants. This enables targeted, localized delivery directly to diseased tissue, whether within an osteoarthritic joint or at a tumor site, supporting higher local concentrations while reducing systemic exposure and off-target effects.
About Us
VetrixBio is focused on improving the lives of companion animals through the development of innovative biotherapeutics, with a focus on osteoarthritis and cancer. Our approach centers on translating cutting-edge scientific advances into practical veterinary therapies that address significant unmet needs.
Our team brings together veterinarians, researchers, and experienced business leaders with deep expertise in developing and commercializing therapies across both animal and human health. This combination enables a translational strategy, applying insights and breakthroughs from human medicine to accelerate innovation and improve outcomes in veterinary care.
Across our pipeline, we are leveraging advances in biologics and immunotherapy to reshape treatment paradigms. In osteoarthritis, our focus extends beyond pain management to disease-modifying and potentially regenerative approaches, reflecting our broader commitment to delivering more durable and impactful therapies. In oncology, we aim to make next-generation immunotherapies more accessible for pets, building on decades of progress in human medicine.